Response to letter to the editor regarding "Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data"

Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):110-111. doi: 10.1002/pds.5376. Epub 2021 Oct 27.

¹ HealthCore, Inc., Wilmington, Delaware, USA.
² RTI Health Solutions, Waltham, Massachusetts, USA.
³ Anthem, Inc., Indianapolis, Indiana, USA.
⁴ Sanofi, Paris, France.
⁵ Division of General Pediatrics, Department of Pediatrics, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.
⁶ Harvard University, Cambridge, Massachusetts, USA.
⁷ Allergy & Asthma Associates of Southern California, San Jose, California, USA.
⁸ Allergy Partners of Central Indiana, Indianapolis, Indiana, USA.
⁹ Scripps Health and SMHE, San Diego, California, USA.
¹⁰ Lower Bucks Hospital, Bristol, Pennsylvania, USA.

No abstract available

Publication types